| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 3 | |
| #2 | Canada | 2 | |
| #3 | Republic of Korea | 2 | |
| #4 | New Zealand | 2 | |
| #5 | China | 1 | |
| #6 | EPO (European Patent Office) | 1 | |
| #7 | Israel | 1 | |
| #8 | Mexico | 1 | |
| #9 | WIPO (World Intellectual Property Organization) | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Therapeutic chemical compounds | |
| #3 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Krilla Nicole D | 9 |
| #2 | Nixon Lori | 9 |
| #3 | Hayes Thomas K | 9 |
| #4 | Bonniaud Philippe | 1 |
| #5 | Garrido Carmen | 1 |
| #6 | Rabinovich-Guilatt Laura | 1 |
| #7 | Kaye Joel | 1 |
| #8 | Kashi Rina | 1 |
| #9 | Elgart Anna | 1 |
| #10 | Wettstein Guillaume | 1 |
| Publication | Filing date | Title |
|---|---|---|
| US2015126584A1 | Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors | |
| CA2900533A1 | Anti-clusterin monotherapy for cancer treatment | |
| CA2903239A1 | Custirsen treatment with reduced toxicity | |
| NZ589262A | Antisense formulation |